Phase II trial of PM 01183 as second-line therapy in patients with metastatic pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors PharmaMar
- 07 Apr 2014 Results from a retrospective study conducted using data from this trial have been presented at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) according to a PharmaMar media release.
- 10 Mar 2012 Planned end date 5 Feb 2014 added as reported by EudraCT.
- 16 Nov 2011 Planned patient number is 43 as reported by European Clinical Trials Database record.